Invivyd (IVVD) Net Cash Flow (2021 - 2025)
Invivyd's (IVVD) quarterly Net Cash Flow came in at $141.7 million in Q4 2025, up 477.64% YoY from $24.5 million in Q4 2024, and up 183.09% on a QoQ basis from $50.1 million in Q3 2025.
Invivyd (IVVD) Net Cash Flow (2021 - 2025) Analysis & Trends
Invivyd (IVVD) has 5 years of Net Cash Flow data on file, last reported at $141.7 million in Q4 2025.
- Quarterly Net Cash Flow rose 477.64% year-over-year to $141.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $157.3 million (up 219.83% YoY) and the FY2025 annual result came in at $157.3 million, up 219.83% from the prior year.
- Net Cash Flow improved to $141.7 million in Q4 2025, from $50.1 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $301.3 million in Q2 2021 to a low of -$196.7 million in Q3 2022.
- A 5-year average of $5.6 million and a median of -$10.6 million in 2022 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2024 — Net Cash Flow slumped 817.08% — and 2025, when it surged 477.64%.
- Tracing IVVD's Net Cash Flow over 5 years: stood at $64.0 million in 2021, then tumbled by 390.95% to -$186.1 million in 2022, then soared by 110.11% to $18.8 million in 2023, then sank by 299.42% to -$37.5 million in 2024, then surged by 477.64% to $141.7 million in 2025.
- The last three Net Cash Flow figures came in at $141.7 million (Q4 2025), $50.1 million (Q3 2025), and -$13.2 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Invivyd | 212.23 Mn | 52.15 Mn | 13.01 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 141.72 Mn |
| Dec 31, 2025 | 141.72 Mn |
| Sep 30, 2025 | 50.06 Mn |
| Sep 30, 2025 | 50.06 Mn |
| Jun 30, 2025 | -13.18 Mn |
| Jun 30, 2025 | -13.18 Mn |
| Mar 31, 2025 | -21.26 Mn |
| Mar 31, 2025 | -21.26 Mn |
| Dec 31, 2024 | -37.53 Mn |
| Dec 31, 2024 | -37.53 Mn |
| Sep 30, 2024 | -41.01 Mn |
| Sep 30, 2024 | -41.01 Mn |
| Jun 30, 2024 | -41.51 Mn |
| Jun 30, 2024 | -41.51 Mn |
| Mar 31, 2024 | -11.25 Mn |
| Mar 31, 2024 | -11.25 Mn |
| Dec 31, 2023 | 18.82 Mn |
| Dec 31, 2023 | 18.82 Mn |
| Sep 30, 2023 | 59.88 Mn |
| Sep 30, 2023 | 59.88 Mn |